N@N

Vamil Divan Maintained (VERA) at Strong Buy with Increased Target to $56 on, Mar 27th, 2024

Vamil Divan of Guggenheim, Maintained "Vera Therapeutics, Inc." (VERA) at Strong Buy with Increased Target from $27 to $56 on, Mar 27th, 2024.

Vamil has made no other calls on VERA in the last 4 months.

There are 6 other peers that have a rating on VERA. Out of the 6 peers that are also analyzing VERA, 1 agrees with Vamil's Rating of Hold. Following is the relevant analyst calls for the last 4 months

---

• Laura Chico of "Wedbush" Maintained at Hold with Increased Target to $34 on, Thursday, March 21st, 2024

These are the ratings of the 5 analyists that currently disagree with Vamil

---

• Steven Seedhouse of "Raymond James" Upgraded from Buy to Strong Buy and Increased Target to $37 on, Friday, January 26th, 2024
• Justin Kim of "Oppenheimer" Initiated at Buy and Held Target at $26 on, Thursday, January 25th, 2024
• Pete Stavropoulos of "Cantor Fitzgerald" Initiated at Buy on, Monday, January 8th, 2024
• Ed Arce of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $25 on, Wednesday, December 27th, 2023
• Anupam Rama of "JP Morgan" Maintained at Buy with Decreased Target to $22 on, Thursday, November 30th, 2023

Contributing Sources

---